TransMedics Group (TMDX) delivers strong 2025 growth and projects 20–25% higher 2026 revenue
Rhea-AI Filing Summary
TransMedics Group, Inc. reported strong growth for the fourth quarter and full year 2025, driven by broader use of its Organ Care System and related services. Fourth quarter revenue reached
Net income jumped to
TransMedics completed 5,139 U.S. NOP cases in 2025, expanded its owned aviation fleet to 22 aircraft, and received FDA approval for key heart and lung trials. For 2026, it projects revenue between
Positive
- Strong top-line growth and scale: 2025 revenue reached
$605.5 million , up37% year over year, with fourth quarter revenue up32% , showing robust adoption of the OCS platform and NOP services. - Profitability with expanding scale: 2025 net income was
$190.3 million , including an$82.8 million tax benefit, while gross margin improved to60% , indicating operating leverage as volumes increase. - Confident 2026 outlook: Revenue guidance of
$727–$757 million for 2026 implies20–25% growth over 2025, signaling management’s expectation of continued strong demand and pipeline execution.
Negative
- None.
Insights
TransMedics posted rapid revenue growth, rising profitability, and double-digit 2026 guidance.
TransMedics delivered full year 2025 revenue of
Net income climbed to
Management completed 5,139 U.S. NOP cases and grew its owned aircraft fleet to 22, reinforcing control over transplant logistics. For the year ending
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 24, 2026, TransMedics Group, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
Description |
|
|
|
99.1 |
|
Press release issued by TransMedics Group, Inc. on February 24, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
TRANSMEDICS GROUP, INC. |
|
|
|
|
Date: |
February 24, 2026 |
By: |
/s/ Gerardo Hernandez |
|
|
|
Name: Gerardo Hernandez |
Exhibit 99.1
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
Andover, Mass. – February 24, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025.
Recent Highlights
“We are very pleased with our fourth quarter and full year 2025 performance. These results reflect strong execution, continued adoption of our OCSTM NOPTM program, and disciplined investment to support sustained long-term growth,” said Waleed Hassanein, M.D., President and Chief Executive Officer. “We have several strategic growth initiatives lined up for 2026 to catalyze growth short, mid- and long-term for TransMedics. We are laser focused on executing on these initiatives by accelerating heart and lung adoption in the US through our ongoing clinical programs, launching our NOP model in Europe, and preparing for the clinical launch of
our OCS Kidney program. Achieving our goals would make 2026 another transformative year for TransMedics and catalyze our growth for the next several years, while advancing our mission to expand access and improve clinical outcomes for transplant patients globally.”
Fourth Quarter 2025 Financial Results
Total revenue for the fourth quarter of 2025 was $160.8 million, a 32% increase compared to $121.6 million in the fourth quarter of 2024. The increase was due primarily to the increase in utilization of the Organ Care System ("OCS"), primarily in Liver and Heart through the National OCS Program ("NOP") and related NOP service revenue fueled by the continued expansion and utilization of our aviation fleet.
Gross margin for the fourth quarter of 2025 was 58%, compared to 59% in the fourth quarter of 2024. The change from prior year is a result of higher clinical service expenses in support of NOP expansion and higher freight cost.
Operating expenses for the fourth quarter of 2025 were $72.1 million, compared to $63.4 million in the fourth quarter of 2024. The increase in operating expenses was driven primarily by increased research and development investment as well as investment throughout the organization to support the growth of the company. Fourth quarter operating expenses in 2025 included $9.1 million of stock compensation expense compared to $10.4 million of stock compensation expense in the fourth quarter of 2024.
Net income for the fourth quarter of 2025 was $105.4 million, or 66% of revenue, compared to $6.9 million in the fourth quarter of 2024. This includes a net income tax benefit of $83.8 million, primarily driven by a one-time benefit of $103.3 million from the release of the Company’s valuation allowance related to deferred tax assets.
Full Year 2025 Financial Results
Total revenue for the full year of 2025 was $605.5 million, an 37% increase compared to $441.5 million for the full year of 2024. The increase was driven primarily by the increase in utilization of the OCS across all three organs through the NOP as well as additional revenue generated by TransMedics logistics services.
Gross margin for the full year of 2025 was 60%, compared to 59% in the full year of 2024. The change from prior year was a result of increased efficiencies in transplant logistics and benefits of scale.
Operating expenses for the full year of 2025 were $254.2 million, compared to $224.6 million in the full year of 2024. The increase in operating expense was driven primarily by increased research and development investment as well as investment throughout the organization to support the growth of the company. Full year operating expenses in 2025 included $35.5 million of stock compensation expense compared to $31.7 million of stock compensation expense in the full year of 2024.
Net income for the full year of 2025 was $190.3 million, or 31% of revenue, compared to $35.5 million in the full year of 2024. This includes a net income tax benefit of $82.8 million, primarily driven by a one-time benefit of $103.3 million from the release of the Company’s valuation allowance related to deferred tax assets.
Cash was $488.4 million as of December 31, 2025 compared to $466.2 million as of September 30, 2025.
2026 Financial Outlook
TransMedics expects total revenue for the full year 2026 to be in the range of $727 million to $757 million, which represents 20% to 25% growth compared to the company’s prior year revenue.
Webcast and Conference Call Details
The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Tuesday, February 24, 2026. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 8036478. A live and archived webcast of the event and the company's slide presentation with information on fourth quarter and full year 2025 financial results will be available on the "Investors" section of the TransMedics website at www.transmedics.com.
About TransMedics Group, Inc.
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including financial guidance and projected estimates, growth initiatives for our business both in the U.S. and globally, our strategic initiatives to catalyze short, mid- and long-term growth in 2026 and over the next several years, our goals for 2026 and our focus on accelerating heart and lung transplant adoption in the U.S., launching our NOP model in Europe and preparing for the launch for OCS kidney program, and advancing our mission to expand access and improve clinical outcomes for transplant patients globally. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to
which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train and retain key personnel; our dependence on the success of the Organ Care System ("OCS"); our ability to expand access to the OCS through our National OCS Program ("NOP"); our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications, and the development, and potential commercialization of our OCS Kidney device; the timing or results of clinical trials for the OCS, including pre- and post-approval studies; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration ("FDA"), or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation or administrative actions affecting or reforming the U.S. healthcare system, Organ Procurement and Transplantation Network (“OPTN”), or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our transplant logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration ("FAA") or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of a shutdown of the U.S. government; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; our existing and any future indebtedness, including
our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; the impact of any product recalls or improper use of our products; our international expansion plans and the costs related thereto; our estimates regarding revenue, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Investor Contact:
Brian Johnston
Laine Morgan
Gilmartin Group
332-895-3222
Investors@transmedics.com
TransMedics Group, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
|
|
Three Months Ended December 31, |
|
|
Year Ended December 31, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net product revenue |
|
$ |
100,390 |
|
|
$ |
74,948 |
|
|
$ |
372,401 |
|
|
$ |
273,866 |
|
Service revenue |
|
|
60,374 |
|
|
|
46,676 |
|
|
|
233,093 |
|
|
|
167,674 |
|
Total revenue |
|
|
160,764 |
|
|
|
121,624 |
|
|
|
605,494 |
|
|
|
441,540 |
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of net product revenue |
|
|
23,402 |
|
|
|
16,545 |
|
|
|
77,822 |
|
|
|
58,345 |
|
Cost of service revenue |
|
|
43,948 |
|
|
|
33,066 |
|
|
|
164,866 |
|
|
|
121,114 |
|
Total cost of revenue |
|
|
67,350 |
|
|
|
49,611 |
|
|
|
242,688 |
|
|
|
179,459 |
|
Gross profit |
|
|
93,414 |
|
|
|
72,013 |
|
|
|
362,806 |
|
|
|
262,081 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Gross margin |
|
|
58 |
% |
|
|
59 |
% |
|
|
60 |
% |
|
|
59 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research, development and clinical trials |
|
|
20,701 |
|
|
|
16,464 |
|
|
|
69,055 |
|
|
|
55,968 |
|
Selling, general and administrative |
|
|
51,440 |
|
|
|
46,905 |
|
|
|
185,168 |
|
|
|
168,617 |
|
Total operating expenses |
|
|
72,141 |
|
|
|
63,369 |
|
|
|
254,223 |
|
|
|
224,585 |
|
Income from operations |
|
|
21,273 |
|
|
|
8,644 |
|
|
|
108,583 |
|
|
|
37,496 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
(3,354 |
) |
|
|
(3,571 |
) |
|
|
(13,782 |
) |
|
|
(14,409 |
) |
Interest income and other income (expense), net |
|
|
3,714 |
|
|
|
1,916 |
|
|
|
12,721 |
|
|
|
12,693 |
|
Total other income (expense), net |
|
|
360 |
|
|
|
(1,655 |
) |
|
|
(1,061 |
) |
|
|
(1,716 |
) |
Income before income taxes |
|
|
21,633 |
|
|
|
6,989 |
|
|
|
107,522 |
|
|
|
35,780 |
|
(Provision) benefit for income taxes |
|
|
83,750 |
|
|
|
(132 |
) |
|
|
82,769 |
|
|
|
(316 |
) |
Net income |
|
$ |
105,383 |
|
|
$ |
6,857 |
|
|
$ |
190,291 |
|
|
$ |
35,464 |
|
Net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
3.08 |
|
|
$ |
0.20 |
|
|
$ |
5.60 |
|
|
$ |
1.07 |
|
Diluted |
|
$ |
2.62 |
|
|
$ |
0.19 |
|
|
$ |
4.87 |
|
|
$ |
1.01 |
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
34,220,360 |
|
|
|
33,592,408 |
|
|
|
33,993,468 |
|
|
|
33,229,953 |
|
Diluted |
|
|
40,927,898 |
|
|
|
35,211,121 |
|
|
|
40,540,694 |
|
|
|
35,216,837 |
|
TransMedics Group, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
|
|
December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash |
|
$ |
488,366 |
|
|
$ |
336,650 |
|
Accounts receivable |
|
|
84,282 |
|
|
|
97,722 |
|
Inventory |
|
|
48,881 |
|
|
|
46,554 |
|
Prepaid expenses and other current assets |
|
|
16,254 |
|
|
|
16,290 |
|
Total current assets |
|
|
637,783 |
|
|
|
497,216 |
|
Property, plant and equipment, net |
|
|
327,656 |
|
|
|
285,970 |
|
Operating lease right-of-use assets |
|
|
5,155 |
|
|
|
6,481 |
|
Deferred tax assets |
|
|
83,543 |
|
|
|
— |
|
Restricted cash |
|
|
500 |
|
|
|
500 |
|
Goodwill |
|
|
11,549 |
|
|
|
11,549 |
|
Acquired intangible assets, net |
|
|
1,948 |
|
|
|
2,152 |
|
Other non-current assets |
|
|
239 |
|
|
|
208 |
|
Total assets |
|
$ |
1,068,373 |
|
|
$ |
804,076 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
10,350 |
|
|
$ |
10,292 |
|
Accrued expenses and other current liabilities |
|
|
62,740 |
|
|
|
45,152 |
|
Current portion of long-term debt |
|
|
10,000 |
|
|
|
— |
|
Deferred revenue |
|
|
2,905 |
|
|
|
1,742 |
|
Operating lease liabilities |
|
|
3,310 |
|
|
|
2,727 |
|
Total current liabilities |
|
|
89,305 |
|
|
|
59,913 |
|
Convertible senior notes, net |
|
|
452,804 |
|
|
|
449,939 |
|
Long-term debt, net |
|
|
49,587 |
|
|
|
59,372 |
|
Operating lease liabilities, net of current portion |
|
|
3,577 |
|
|
|
6,249 |
|
Total liabilities |
|
|
595,273 |
|
|
|
575,473 |
|
Total stockholders’ equity |
|
|
473,100 |
|
|
|
228,603 |
|
Total liabilities and stockholders’ equity |
|
$ |
1,068,373 |
|
|
$ |
804,076 |
|
FAQ
How did TransMedics Group (TMDX) perform financially in full year 2025?
What were TransMedics Group (TMDX) fourth quarter 2025 results?
What revenue guidance did TransMedics Group (TMDX) provide for 2026?
How profitable is TransMedics Group (TMDX) and what drove 2025 net income?
What operational milestones did TransMedics Group (TMDX) achieve in 2025?
What is driving TransMedics Group (TMDX) revenue growth across products and services?
Filing Exhibits & Attachments
2 documentsPress Releases
